A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

NCT04172597 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic business decision (unrelated to safety)

Conditions

Breast Cancer
Colorectal Cancer
Solid Tumor
Glioblastome Multiforme

Interventions

DRUG: Poziotinib Hydrochloride
DRUG: Loperamide

Sponsor

Spectrum Pharmaceuticals, Inc